secwatch.observer — SEC 8-K summary
======================================

Issuer:     PROTHENA CORP PUBLIC LTD CO (PRTA)
CIK:        0001559053
Form:       8-K
Filed at:   2023-08-03T23:59:59+00:00
Accession:  0001559053-23-000025
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Prothena Q2 net loss $54.6M, revises FY cash guidance up to ~$600M
------------------------------------------------------------------

- Net loss $54.6M ($1.03/share) vs $41.2M loss in Q2 2022; revenue $4.0M (up from $1.3M).
- Cash, equivalents $661.3M at June 30; year-end cash guidance raised to ~$600M midpoint from $512M.
- Bristol Myers Squibb exercised $55M option for worldwide rights to PRX005 (anti-tau) in July 2023.
- PRX012 Phase 1 topline data expected year-end 2023; IND filing for PRX123 dual vaccine expected year-end.
- Billy Dunn (former FDA Office of Neuroscience Director) added to Board.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1559053/000155905323000025/0001559053-23-000025-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1559053/000155905323000025/prta-20230803.htm
  HTML page:      https://secwatch.observer/filing/0001559053-23-000025

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer